Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas

• Published in: Human pathology Vol. 129; pp. 21 - 31
• Main Authors: Zhang, Zijuan, Pang, Junyi, Chen, Longyun, Chen, Jingci, Li, Junjie, Liu, Hangqi, Wang, Jing, Wu, Huanwen, Liang, Zhiyong
• Format: Journal Article
• Language: English
• Published: United States Elsevier Limited 01-11-2022
• Subjects: Cloning; Colonic Neoplasms - diagnosis; Colorectal cancer; DNA methylation; DNA Mismatch Repair; FDA approval; Humans; Immunohistochemistry; Kinases; Monoclonal antibodies; Mutation; Tropomyosin; Tumors; United States > US; Germany; Immunohistochemistry; NTRK fusion; Colorectal carcinoma; pan-TRK
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2022.08.001

We have previously revealed the high enrichment of NTRK fusion in mismatch repair deficient (dMMR) CRCs. Optimized diagnostic approaches are urgently needed to identify dMMR CRCs that could benefit from TRK inhibitor therapy. A consecutive cohort of 240 surgically resected dMMR CRCs from 2015 to 2021 was collected for pan-TRK immunohistochemistry (IHC) using pan-TRK clone EPR17341 (VENTANA). We analyzed the sensitivity and specificity of pan-TRK IHC with sequential DNA/RNA-based Next Generation Sequencing (NGS) as the reference method and further explored IHC staining patterns and their correlation with fusion variants in dMMR CRCs. Of 240 dMMR CRCs, 15 (6.2%) were stained positive for pan-TRK IHC, and the sensitivity and specificity were both 100%. Five staining patterns were revealed, which correlated with fusion variants. Diffuse and strong positivity in membrane and cytoplasm were detected in all 6 cases with TPM3-NTRK1 fusions (6/15, 40%). Weak granular cytoplasmic staining, including diffuse or focal positivity, was found in 6 NTRK3 fusions (3 ETV6-NTRK3 and 3 EML4-NTRK3) (6/15, 40%). Diffuse and strong nuclear positivity was noticed in 2 LMNA-NTRK1 fusions (2/15, 13.3%). Intense granular cytoplasmic staining was observed in the only case with PLEKHA6-NTRK1 fusion (1/15, 6.7%). Interestingly, pan-TRK positivity was observed in one case with precursor lesions in both precancerous and cancerous regions, whereas MLH1 loss was restricted to the cancerous region. In summary, an optimized multi-step algorithm using pan-TRK IHC as a screening method was proposed to identify CRC patients harboring NTRK fusions.